Scinai Immunotherapeutics (SCNI) Long-Term Deferred Tax (2022 - 2025)

Scinai Immunotherapeutics has disclosed Long-Term Deferred Tax across 4 years of filings, most recently posting $28.1 million for Q4 2025.

• Long-Term Deferred Tax for Q4 2025 came in at $28.1 million, up 20.04% year-over-year; the trailing twelve-month figure through Dec 2025 was $28.1 million (up 20.04% YoY), and the FY2025 annual result was $28.1 million, up 20.04% from the prior year.
• Long-Term Deferred Tax came in at $28.1 million for Q4 2025 at Scinai Immunotherapeutics, up from $23.4 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $28.1 million in Q4 2025 to a low of $22.0 million in Q4 2022.
• The 4-year median for Long-Term Deferred Tax is $24.8 million (2023), against an average of $24.9 million.
• Across the five-year window, Long-Term Deferred Tax slipped 10.63% in 2024 and gained 20.04% in 2025, its largest moves.
• Scinai Immunotherapeutics' Long-Term Deferred Tax stood at $22.0 million in 2022, then rose by 18.97% to $26.2 million in 2023, then dropped by 10.63% to $23.4 million in 2024, then gained by 20.04% to $28.1 million in 2025.
• The last three Long-Term Deferred Tax figures came in at $28.1 million (Q4 2025), $23.4 million (Q4 2024), and $26.2 million (Q4 2023), per Business Quant data.